Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ABCC4/MRP4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ABCC4 Intracellular Domains (NBD1/NBD2) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ABCC4 Products |
| Gene Delivery | ABCC4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native 12-transmembrane conformation. |
View ABCC4 Products |
| Benchmark Ab | Anti-ABCC4 Recombinant Antibody Recombinant positive control for expression validation. |
View ABCC4 Products |
| Validator | ABCC4 siRNA Set For knockdown verification. |
View ABCC4 Products |
| Related Target A | ABCC1 (MRP1) Subfamily homolog for selectivity and off-target toxicity screening. |
View ABCC1 Products |
| Related Target B | ABCB1 (P-gp) Major multidrug resistance transporter for profiling efflux cross-reactivity. |
View ABCB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex 12-transmembrane conformation maintenance | Lentiviral vectors for stable overexpressing cell line generation (preserves native transport activity) |
| Subfamily counter screening (MRP1, MRP2, MRP3, MRP5) | Sequence-verified homolog proteins and target-specific siRNA validation sets |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live ABCC4/MRP4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ABCC4/MRP4 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum chemosensitizers to highly selective small molecule inhibitors and targeted degraders (PROTACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting specific intracellular nucleotide-binding domains to overcome multidrug resistance in oncology and modulate inflammatory signaling pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Pancreatic Cancer, Neuroblastoma | Efflux Inhibition Assay (Need Lentivirus for stable cell line construction) |
| PROTACs / Degraders | Targeted Protein Degradation Pioneers | Drug-Resistant Solid Tumors | Target Binding & Ubiquitination (Need recombinant NBD domains) |
| RNA Therapeutics | Oligonucleotide Therapeutics Developers | Inflammatory Diseases, Pain | Target Knockdown Validation (Need sequence-verified siRNA sets) |